TRANSGENE BIOTEK LTD. SHARE PRICE [LIVE]
| Open: | |
| High: | |
| Low: |
| MKT Cap: | |
| 52-wk High: | |
| 52-wk Low: |
| Prev close: | |
| P/E: | |
| Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
| Name | Dec 22 | Sep 22 |
|---|---|---|
| Promoters (Change:0.00) | 23.64% | 23.64% |
| FIIs (Change:0.00) | 0% | 0% |
| Mutual Funds (Change:0.00) | 0% | 0% |
| Insurance Companies (Change:0.00) | 0% | 0% |
| Other DIIs (Change:0.00) | 0% | 0% |
| Non Institution (Change:-0.00) | 76.36% | 76.36% |
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in TRANSGENE BIOTEK LTD.
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
TRABI News
Frequently Asked Questions
What is the Share price of TRANSGENE BIOTEK LTD. (TRABI)?
Can I buy TRANSGENE BIOTEK LTD. (TRABI) shares?
How do I buy TRANSGENE BIOTEK LTD. (TRABI) from Angel One?
- Direct investment: You can buy TRANSGENE BIOTEK LTD. (TRABI) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to TRANSGENE BIOTEK LTD. (TRABI) shares.
In which sector do TRANSGENE BIOTEK LTD. (TRABI) belong?
About TRABI
Today's live share price for TRANSGENE BIOTEK LTD. is NSE: N/A, BSE: ₹ 2.36 with a current market capitalization of .
Transgene Biotek was incorporated as a private limited company in Mar.'90 and was converted into a public limited company in Nov.'90. The company is engaged in the research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for the qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively. Transgene Biotek's products are exported to Africa, Russia, China, Malaysia and the Phillipines. The company chalked out a new project for setting up a manufacturing facility at a cost of Rs.30 crore at the Anrich Industrial Area,Bollaram. TBL is working of four new plants:Oral deliver of proteins and peptides:DNA vaccines:fusion proteins and bio therapeutics. The new project is being funded by way of preferential offer to Batterymarch Financial management USA and other financial institutions.
Read more
